{
    "nct_id": "NCT00441987",
    "title": "A Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 Administered Orally to Healthy Japanese Male Subjects and Healthy Elderly Male Japanese Subjects.",
    "status": "COMPLETED",
    "last_update_time": "2022-04-28",
    "description_brief": "The purpose of the protocol is to assess the initial pharmacokinetic (PK) profile of a single oral dose of GSI-953 to healthy male Japanese subjects and healthy elderly male Japanese subjects.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "GSI-953",
        "begacestat (GSI-953)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The protocol tests GSI-953 (begacestat) \u2014 a small\u2011molecule, thiophene sulfonamide \u03b3\u2011secretase inhibitor developed to reduce production of amyloid\u2011\u03b2 peptides by inhibiting \u03b3\u2011secretase cleavage of APP, i.e., it targets Alzheimer\u2019s pathology (amyloid). \ue200cite\ue202turn0search1\ue202turn0search6\ue202turn0search0\ue201",
        "Act (web evidence): Multiple sources identify GSI\u2011953 as begacestat and describe its mechanism and biomarker effects \u2014 selective inhibition of APP versus Notch, dose\u2011dependent reductions in A\u03b2 in animal models and reductions in plasma A\u03b2 in human single\u2011dose studies (PK/PD). These findings support that GSI\u2011953 is a disease\u2011targeting small molecule rather than a biologic or symptomatic/cognitive enhancer. \ue200cite\ue202turn0search3\ue202turn0search2\ue202turn0search4\ue201",
        "Reflect: Classification check \u2014 per the definitions: it is not a biologic (it's a synthetic small molecule), it directly targets Alzheimer\u2019s pathology (amyloid generation), and its intended effect is disease\u2011targeted (modulating A\u03b2 production). Therefore the correct category is 'disease-targeted small molecule'. No substantial ambiguity in the available descriptions; the trial described is a PK/PD single\u2011dose study in healthy subjects, which is consistent with early clinical development of a disease\u2011targeted small molecule. \ue200cite\ue202turn0search1\ue202turn0search3\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational agent is GSI-953 (begacestat), a small\u2011molecule \u03b3\u2011secretase inhibitor developed to reduce generation of amyloid\u2011\u03b2 peptides by inhibiting \u03b3\u2011secretase cleavage of APP \u2014 i.e., it directly targets amyloid production, which is CADRO category A. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Act: Extracted facts from the trial description and literature \u2014 drug names: GSI\u2011953, begacestat; mechanism: thiophene sulfonamide \u03b3\u2011secretase inhibitor, selective for APP versus Notch; PD/biomarker evidence: dose\u2011dependent reductions in plasma, CSF and brain A\u03b2 in preclinical models and single\u2011dose human studies (PK/PD). These sources describe direct engagement of the amyloid pathway rather than unrelated pathways. \ue200cite\ue202turn0search2\ue202turn0search0\ue202turn0search3\ue201",
        "Reflect: Classification check \u2014 the compound is a disease\u2011targeted small molecule whose primary mechanistic intent is to lower A\u03b2 production (amyloid pathology). That maps directly to CADRO A) Amyloid beta. There is no indication here of a multi\u2011target therapy or a non\u2011therapeutic diagnostic; hence 'A) Amyloid beta' is the appropriate, specific category. \ue200cite\ue202turn0search1\ue202turn0search4\ue201",
        "Web search results (key sources used):",
        "- Begacestat (GSI\u2011953) preclinical/pharmacology description (J Pharmacol Exp Ther / PubMed) \u2014 describes selective \u03b3\u2011secretase inhibition, APP vs Notch selectivity, and reductions in brain/plasma/CSF A\u03b2. \ue200cite\ue202turn0search2\ue202turn0search1\ue201",
        "- ACS Chemical Neuroscience summary and data on begacestat pharmacology and single\u2011dose human PD effects. \ue200cite\ue202turn0search0\ue201",
        "- Tocris / Bio\u2011Techne product descriptions summarizing begacestat as a \u03b3\u2011secretase inhibitor lowering A\u03b240/A\u03b242. \ue200cite\ue202turn0search3\ue202turn0search4\ue201"
    ]
}